BioCentury
ARTICLE | Company News

Amgen appeals biosimilar case to CAFC

March 26, 2015 2:02 AM UTC

Amgen Inc. (NASDAQ:AMGN) filed an appeal to the U.S. Court of Appeals for the Federal Circuit (CAFC) Wednesday, after a district court last week denied the company's motions intended to prevent the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) from launching Zarxio filgrastim-sndz, a biosimilar of Amgen's Neupogen filgrastim.

Yesterday, Amgen filed a motion with the district court for a preliminary injunction that would delay Sandoz's launch of Zarxio until the CAFC resolves Amgen's appeal. The district court hearing is scheduled for April 30, but both companies have requested a hearing date as early as April 2. If the motion is denied, Amgen said it will file a motion for an injunction pending appeal with the CAFC. ...